Stockscreener 앱 받기
2.02
4.72%
-0.10
시간 외 거래:
2.05
0.03
+1.49%
전일 마감가:
$2.12
열려 있는:
$2.08
하루 거래량:
9.99M
Relative Volume:
0.67
시가총액:
$730.94M
수익:
$241.53M
순이익/손실:
$-389.92M
주가수익비율:
-1.6423
EPS:
-1.23
순현금흐름:
$-323.54M
1주 성능:
-8.18%
1개월 성능:
-20.16%
6개월 성능:
-41.95%
1년 성능:
-78.09%
1일 변동 폭
$1.97
$2.085
1주일 범위
$1.97
$2.2399
52주 변동 폭
$1.6385
$12.51
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
명칭
Iovance Biotherapeutics Inc
전화
(650) 260-7120
주소
825 INDUSTRIAL ROAD, SAN CARLOS
IOVA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
2.02 | 767.13M | 241.53M | -389.92M | -323.54M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
381.87 | 96.56B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.58 | 60.08B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.51 | 61.15B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
711.09 | 44.66B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
328.71 | 36.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-05-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-05-12 | 다운그레이드 | Truist | Buy → Hold |
| 2025-05-09 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-07-29 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | 개시 | Goldman | Buy |
| 2023-09-18 | 재확인 | Barclays | Overweight |
| 2023-05-30 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | 재개 | Wells Fargo | Equal Weight |
| 2023-01-27 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-10-31 | 개시 | Guggenheim | Neutral |
| 2022-08-18 | 재개 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Stifel | Hold → Buy |
| 2021-12-07 | 재개 | Cowen | Outperform |
| 2021-06-10 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-05-03 | 개시 | Truist | Buy |
| 2021-04-16 | 개시 | Goldman | Buy |
| 2021-03-08 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | 개시 | Mizuho | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-02-26 | 재확인 | Oppenheimer | Outperform |
| 2019-12-18 | 개시 | JMP Securities | Mkt Outperform |
| 2019-10-01 | 개시 | Stifel | Buy |
| 2019-04-29 | 개시 | Piper Jaffray | Overweight |
| 2019-02-28 | 재확인 | Chardan Capital Markets | Buy |
| 2019-02-07 | 개시 | Robert W. Baird | Outperform |
| 2018-12-31 | 재개 | B. Riley FBR | Buy |
| 2018-07-06 | 재확인 | Chardan Capital Markets | Buy |
| 2018-04-10 | 업그레이드 | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | 재확인 | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | 재확인 | H.C. Wainwright | Buy |
| 2017-11-01 | 재확인 | B. Riley FBR, Inc. | Buy |
모두보기
Iovance Biotherapeutics Inc 주식(IOVA)의 최신 뉴스
Healthcare's Convergence Accelerates as Aging Demographics Meet Breakthrough Therapies - Baystreet.ca
Revenue Check: Can Iovance Biotherapeutics Inc deliver consistent EPS growthTrade Entry Report & AI Enhanced Execution Alerts - خودرو بانک
Iovance Biotherapeutics (NASDAQ:IOVA) Share Price Crosses Below Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Iovance Biotherapeutics, Inc. (IOVA): Among Stocks Under $10 that Will Triple - MSN
Published on: 2025-09-21 02:39:03 - خودرو بانک
Buy Signal: Can Iovance Biotherapeutics Inc grow without dilutionJuly 2025 Retail & AI Enhanced Execution Alerts - khodrobank.com
Valuation Update: Will Iovance Biotherapeutics Inc benefit from AI trendsMarket Activity Recap & Weekly Return Optimization Plans - خودرو بانک
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Iovance Biotherapeutics, Inc. (IOVA) Targeting $1B on Amtagvi Sales amid Cost Cuts - Insider Monkey
22,810 Stock Options at $2.20: Iovance Biotech Expands Team with New Employee Inducement Grants - Stock Titan
Returns Recap: Is Iovance Biotherapeutics Inc likely to announce a buybackDollar Strength & Low Risk High Reward Ideas - khodrobank.com
Decliners Report: Will Iovance Biotherapeutics Inc benefit from green energy policiesTrade Analysis Report & Weekly Watchlist of Top Performers - خودرو بانک
Can This Beaten-Down Stock Bounce Back? - Yahoo Finance
Ema's CHMP recommended five extensions of indication for medicines Bimervax, Dupixent, Keytruda - MarketScreener
Earnings Recap: Why is Iovance Biotherapeutics Inc stock going upJuly 2025 Earnings & Real-Time Buy Signal Alerts - خودرو بانک
Advancing Cancer Research Brings New Hope for Patients Worldwide - Benzinga
Bearish Setup: Can Iovance Biotherapeutics Inc stock double in the next yearJuly 2025 Trade Ideas & Scalable Portfolio Growth Ideas - خودرو بانک
Sectors Review: Is Iovance Biotherapeutics Inc attractive at current valuationFed Meeting & Free Long-Term Investment Growth Plans - خودرو بانک
Why Iovance Biotherapeutics (IOVA) Is Up 8.2% After Health Canada Approves Amtagvi for Melanoma - Sahm
Aug Chart Watch: Is Iovance Biotherapeutics Inc being accumulated by smart moneyGap Up & Weekly Top Performers Watchlists - خودرو بانک
Iovance Biotherapeutics Updates Corporate Presentation - MSN
Aug Breakouts: Is Iovance Biotherapeutics Inc forming a bullish divergenceQuarterly Trade Report & Consistent Profit Trading Strategies - khodrobank.com
Fibrogen leads drug developer stock gains on China sale, FDA update - BioWorld MedTech
Is Iovance Biotherapeutics Inc showing insider buyingTrade Entry Report & Expert-Curated Trade Recommendations - khodrobank.com
Nasdaq Moves: How does Iovance Biotherapeutics Inc score in quality rankingsJuly 2025 Highlights & Entry and Exit Point Strategies - خودرو بانک
Published on: 2025-09-16 06:42:56 - خودرو بانک
Entry Recap: Should I buy Iovance Biotherapeutics Inc. stock now2025 Technical Patterns & Weekly High Conviction Ideas - خودرو بانک
Market Overview: Can Iovance Biotherapeutics Inc. maintain sales growth2025 Retail Activity & Stepwise Swing Trade Plans - خودرو بانک
Stock Analysis: Why is Iovance Biotherapeutics Inc stock going upJuly 2025 Rallies & Capital Protection Trading Alerts - خودرو بانک
Bull Run: Will Iovance Biotherapeutics Inc benefit from AI trends2025 Geopolitical Influence & Entry and Exit Point Strategies - خودرو بانک
RSI Check: What are Iovance Biotherapeutics Inc.’s earnings expectationsEarnings Beat & Real-Time Volume Analysis - خودرو بانک
Iovance falls after missing Q2 expectation - MSN
Jacobs Levy Equity Management Inc. Invests $4.19 Million in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Rating of "Hold" by Brokerages - MarketBeat
Iovance Biotherapeutics, Inc. $IOVA Position Cut by American Century Companies Inc. - MarketBeat
Why Iovance Biotherapeutics Stock Plummeted Today - MSN
Invenomic Capital Management LP Purchases Shares of 5,489,799 Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance Biotherapeutics at H.C. Wainwright Conference: Strategic Growth and Efficiency - Investing.com Canada
Growth Review: Will Iovance Biotherapeutics Inc. stock go up in YEARRisk Management & Stepwise Swing Trade Plans - Lancaster City Council
Is Iovance Biotherapeutics Inc. Forming a Consolidation BaseMarket Activity Report & Weekly Setup with High ROI Potential - beatles.ru
Iovance Biotherapeutics, Inc. $IOVA Shares Sold by Hsbc Holdings PLC - Defense World
H.C. Wainwright Keeps Buy Rating on Iovance (IOVA) After Health Canada Authorization News - Yahoo Finance
Is Iovance Biotherapeutics Inc. a turnaround storyJuly 2025 Pullbacks & Fast Gaining Stock Strategy Reports - beatles.ru
Iovance Biotherapeutics Soars as Health Canada Approves Amtagvi T Cell Therapy - StocksToTrade
Iovance Biotherapeutics Leaps Forward with Health Canada Approval - timothysykes.com
Iovance Biotherapeutics Inc (IOVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.43%
자본화:
|
볼륨(24시간):